Collplant Biotechnologies vs Korro Bio
Korro Bio is the larger business, with $6.4m of revenue in fiscal 2025 against $2.4m for Collplant Biotechnologies (2.7 times as much). Collplant Biotechnologies grew faster (360.4% against 181.5%). Collplant Biotechnologies kept more of each dollar of sales as profit: a net margin of -484.6% against -1834.5%.
| Latest fiscal year | Collplant BiotechnologiesCLGN, 2025 | Korro BioKRRO, 2025 |
|---|---|---|
| Revenue | $2.4m | $6.4m |
| Revenue growth | 360.4% | 181.5% |
| Net income | −$11.5m | −$117m |
| Operating margin | -484.3% | — |
| Net margin | -484.6% | -1834.5% |
| Return on equity | -117.6% | -110.7% |
| Free cash flow | −$9.4m | −$79.1m |
| Cash | $5.6m | $21.8m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 58 |
| Market value | $54.5m | $235m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 16 buys, 33 sales |